Taysha Gene Therapies, Inc.
- Open
- 5.74
- Day high
- 5.78
- Day low
- 5.53
- Prev close
- 5.77
- Volume
- 2.1M
- Mkt cap
- $1.9B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 4.8
- P/S
- 338.0
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.2M over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions reducing (13F)
Taysha Gene Therapies, Inc. (TSHA) is a Healthcare company listed on NASDAQ. The stock is up 97% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 1 published research article covering TSHA.
Taysha Gene Therapies, Inc. (TSHA) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TSHA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 11, 2026 | $-0.11 | $-0.13 | -14.8% | — | — |
| May 6, 2026 | $-0.10 | $-0.12 | -20.0% | — | — |
| Mar 19, 2026 | $-0.11 | $-0.08 | +27.3% | $5M | +144.5% |
| Nov 4, 2025 | $-0.09 | $-0.09 | +0.0% | — | — |
| Aug 12, 2025 | $-0.07 | $-0.09 | -28.6% | $2M | +14.9% |
| May 15, 2025 | $-0.08 | $-0.08 | +0.0% | $2M | +112.3% |
| Feb 26, 2025 | $-0.08 | $-0.07 | +12.5% | $2M | -1.5% |
| Mar 19, 2024 | $-0.09 | $0.35 | +488.9% | $4M | +36.0% |
| Nov 14, 2023 | $-0.13 | $-0.13 | +0.0% | $5M | +79.1% |
| Aug 14, 2023 | $-0.31 | $-0.38 | -22.6% | $2M | +128.1% |
| May 11, 2023 | $-0.35 | $-0.28 | +20.0% | — | — |
| Aug 11, 2022 | $-1.05 | $-0.84 | +20.0% | — | — |
TSHA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 10, 2026 | Nagendran Sukumardirector, officer: President and Head of R&D | Sell | 200,000 | $6.24 |
| Jun 2, 2026 | Long Alison Sdirector | Grant | 21,335 | — |
| Jun 2, 2026 | Long Alison Sdirector | Grant | 42,671 | $5.97 |
| Jun 2, 2026 | Sepp-Lorenzino Lauradirector | Grant | 21,335 | — |
| Jun 2, 2026 | Sepp-Lorenzino Lauradirector | Grant | 42,671 | $5.97 |
| Jun 2, 2026 | Donenberg Phillip B.director | Grant | 42,671 | $5.97 |
| Jun 2, 2026 | Stalfort John A IIIdirector | Grant | 21,335 | — |
| Jun 2, 2026 | Stalfort John A IIIdirector | Grant | 42,671 | $5.97 |
| Jun 2, 2026 | Donenberg Phillip B.director | Grant | 21,335 | — |
| Apr 13, 2026 | Nagendran Sukumardirector, officer: President and Head of R&D | Option | 19,021 | $1.71 |
| Apr 13, 2026 | Nagendran Sukumardirector, officer: President and Head of R&D | Sell | 200,000 | $4.46 |
| Feb 6, 2026 | Alam Kamranofficer: CHIEF FINANCIAL OFFICER | Sell | 1,655 | $4.52 |
| Jan 27, 2026 | Alam Kamranofficer: CHIEF FINANCIAL OFFICER | Sell | 23,849 | $4.61 |
| Jan 27, 2026 | Nagendran Sukumardirector, officer: President and Head of R&D | Sell | 26,918 | $4.61 |
| Jan 27, 2026 | Nolan Sean P.director, officer: Chief Executive Officer | Sell | 136,789 | $4.75 |
Source: TSHA SEC Form 4 filings, latest Jul 10, 2026. For informational purposes only — not investment advice.
See the full TSHA insider & 13F page →Taysha Gene Therapies, Inc. company profile
Overview
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a clinical-stage biotechnology company founded in 2019 and based in Dallas, Texas. The company went public in September 2020 and focuses on developing gene therapies for rare monogenic diseases affecting the central nervous system. Taysha has established a strategic partnership with The University of Texas Southwestern Medical Center to advance transformative gene therapy treatments. The company is currently advancing its lead program TSHA-102 through Phase 1/2 clinical trials for Rett syndrome, having completed dosing of 10 patients with encouraging preliminary results.
Business
Taysha Gene Therapies operates in the gene therapy sector of biotechnology, specifically targeting rare genetic diseases of the central nervous system. Gene therapy is a medical technique that involves introducing genetic material into a patient's cells to treat or prevent disease, essentially providing the body with correct genetic instructions to produce missing or defective proteins. The company's core technology platform utilizes adeno-associated virus (AAV)-based gene therapies, which are engineered viruses that serve as delivery vehicles to transport therapeutic genes into specific cells. AAV vectors are preferred for gene therapy because they are generally considered safe, do not integrate into the host genome randomly, and can target specific tissues effectively. Taysha's primary focus is on monogenic diseases - conditions caused by mutations in a single gene - affecting the central nervous system. These are typically rare, devastating disorders that currently have limited or no treatment options. The company's pipeline includes several programs: 1. TSHA-102 represents approximately 80-90% of the company's current focus, targeting Rett syndrome using their proprietary miRARE technology. Rett syndrome is a severe neurological disorder primarily affecting girls, caused by mutations in the MECP2 gene, leading to developmental regression, loss of motor skills, seizures, and communication difficulties. 2. TSHA-120 targets giant axonal neuropathy (GAN), a rare progressive neurodegenerative disease affecting the peripheral and central nervous systems. 3. Additional earlier-stage programs include TSHA-121 and TSHA-118 for CLN1 disease (a form of neuronal ceroid lipofuscinosis), TSHA-105 for SLC13A5 deficiency, and TSHA-101 for GM2 gangliosidosis. The company's unique miRARE technology allows for precise control of protein expression at the cellular level, potentially avoiding the risks of over-expression that can occur with traditional gene therapy approaches.
Revenue model
Taysha operates under a typical biotech business model focused on research and development with the ultimate goal of commercializing gene therapies. Currently, the company generates minimal revenue (approximately $2-8 million annually) primarily from collaboration agreements and grants, particularly through its partnership with UT Southwestern Medical Center. The company's future revenue model will depend on successfully advancing its gene therapy candidates through clinical trials and regulatory approval. Once approved, gene therapies typically command high prices - often $500,000 to over $2 million per treatment - due to their one-time administration for rare diseases affecting small patient populations. The business model relies on charging premium prices to a limited number of patients rather than high-volume sales. Key factors that could increase profitability include successful clinical trial outcomes, regulatory approvals, and potential partnership deals or licensing agreements with larger pharmaceutical companies. The company's margins could benefit from the high-value nature of gene therapies and the significant unmet medical need in rare diseases. Factors that could negatively impact margins include clinical trial failures, regulatory setbacks, manufacturing complexities and costs associated with AAV vector production, competition from other gene therapy companies, and potential pricing pressure from payers and regulatory agencies. The company faces substantial cash burn during the lengthy development process, with R&D expenses of $66 million in 2024 and operating losses exceeding $80 million annually. Manufacturing gene therapies requires specialized facilities and expertise, creating both high fixed costs and potential supply chain risks.
Competitive moat
Taysha's competitive moat appears moderate but not particularly strong in the current gene therapy landscape. The company's primary differentiation lies in its miRARE technology platform, which provides cellular-level control of protein expression and could potentially offer safety advantages over traditional gene therapy approaches by avoiding over-expression risks. The company's intrathecal delivery method for TSHA-102 represents a potentially less invasive approach compared to direct brain injection methods used by some competitors, though the clinical significance of this advantage remains to be proven. Taysha also benefits from its strategic partnership with UT Southwestern, providing access to research expertise and potentially favorable licensing terms. However, the gene therapy space for neurological disorders is becoming increasingly competitive. Multiple companies are developing treatments for Rett syndrome, including Neurogene, which has shown clinical data with a different delivery approach. The fundamental challenge is that gene therapy approaches for the same target diseases are often quite similar, with differentiation primarily coming from delivery methods, vector design, and clinical execution rather than truly proprietary mechanisms. Taysha's moat is further limited by the fact that successful gene therapies can potentially be replicated or improved upon by competitors with sufficient resources. The company's intellectual property position, while important, may not provide insurmountable barriers to entry for well-funded competitors. Additionally, larger pharmaceutical companies with greater resources could potentially develop competing therapies or acquire promising competitors, posing a significant competitive threat to Taysha's market position.
Risks & safety
Taysha presents a moderate margin of safety typical of clinical-stage biotech companies, with strong liquidity but significant execution risks. • Cash Position: $116.6 million in cash and short-term investments as of Q1 2025, providing runway into Q4 2026 based on current burn rate • Burn Rate: Free cash flow burn of approximately $22 million quarterly ($88 million annually), which is manageable given current cash position • Debt Level: Debt-to-equity ratio of 0.31, indicating moderate leverage without excessive debt burden • Current Ratio: Strong liquidity with current ratio of 5.35, indicating ability to meet short-term obligations • Solvency Risk: Low near-term solvency risk given cash runway, but will likely need additional financing before commercialization • Valuation Metrics: Trading at negative P/E ratios due to losses, with price-to-book ratio of 6.8 suggesting premium valuation relative to tangible assets • Market Cap: Approximately $743 million market capitalization appears high relative to single-asset clinical-stage profile • Other Considerations: Binary clinical and regulatory risks typical of biotech, with success heavily dependent on TSHA-102 program outcomes; competitive landscape in gene therapy creating additional execution pressure
Recent development
Over the past few years, Taysha has undergone a significant strategic transformation from a multi-asset gene therapy company to one primarily focused on its TSHA-102 program for Rett syndrome. This shift represents a concentration of resources on the company's most promising opportunity. The company has made substantial regulatory progress with TSHA-102, achieving FDA alignment on key elements of the pivotal trial design and receiving Regenerative Medicine Advanced Therapy (RMAT) designation. This designation provides enhanced FDA communication and potentially expedited review processes. Taysha has completed dosing of 10 patients across two Phase 1/2 REVEAL trials, demonstrating encouraging safety profiles with no treatment-related serious adverse events or dose-limiting toxicities. Clinical development advances include expansion from adult patients to include pediatric populations, with trials now enrolling patients as young as 15 years old. The company has observed early clinical improvements across multiple domains including motor function, communication, autonomic function, and seizure reduction. Taysha has also expanded its geographic footprint, with regulatory clearance to conduct trials in both the U.S. and U.K. The company has strengthened its leadership team with new Chief Medical Officer and Chief Regulatory Officer appointments to support the advancing clinical programs. Manufacturing capabilities have been enhanced with FDA approval for pivotal product manufacturing. Taysha has also refined its clinical strategy, moving away from certain outcome measures like the Rett Syndrome Behavioral Questionnaire to focus on more objective functional endpoints that align with FDA preferences for demonstrating meaningful clinical benefit.
TSHA company profile · for informational purposes only — not investment advice.
Track TSHA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free